Physician Profile

Robert A. Harrington, MD

Education:
Medical School:
Tufts University School of Medicine, Massachusetts, MD, 1986

Residency:
University of Massachusetts Medical Center, Internal Medicine, 1986-1990

Fellowship:
Duke University Medical Center, North Carolina, Cardiology, 1990-1993

Clinical Interests/Specialties:
Interventional cardiology (PTCA), ischemic heart disease, acute coronary care, cardiovascular clinical trials

Research:
Robert A. Harrington, MD is a Professor of Medicine at Duke University Medical Center and faculty member at the Duke Clinical Research Institute where he serves as the Director.

His research interests include evaluating antithrombotic therapies to treat acute ischemic heart disease and to minimize the acute complications of percutaneous coronary procedures, studying the mechanism of disease of the acute coronary syndromes, understanding the issues of risk stratification in the care of patients with acute ischemic coronary syndromes, trying to better understand and improve upon the methodology of large clinical trials. He is the recipient of an NIH Roadmap contract to investigate "best practices" among clinical trial networks.

He has authored multiple peer-reviewed manuscripts, reviews, book chapters, and editorials. He is one of the senior co-editors for the 8th edition of the American College of Chest Physicians' Consensus Panel on Antithrombotic and Thrombolytic Drugs. He is an Associate Editor of the American Heart Journal and an editorial board member for the Journal of the American College of Cardiology. He is a Fellow of the American College of Cardiology, the American Heart Association, the Society of Cardiovascular Angiography and Intervention and the American College of Chest Physicians. He currently chairs the American College of Cardiology Clinical Expert Consensus Document Task Force and the Education Strategy Committee. He chaired the 2006 Annual Scientific Sessions for the American College of Cardiology. He currently serves as chair of the FDA Cardiovascular and Renal Drugs Advisory Committee, a member of the NHLBI's study section for clinical trials and as a member of the NHLBI Working Group on Clinical Trials Methodology.

Hospital Affiliations:
Duke University Medical Center